TERTmonitor—qPCR Detection of TERTp Mutations in Glioma
Open Access
Abstract
Telomerase promoter (TERTp) mutations are frequently observed in various types of tumours and commonly characterised by two specific hotspots located at positions −124 and −146 upstream of the start codon. They enhance TERTp activity, resulting in increased TERT expression. In central nervous system (CNS) tumours, they are integrated as biomarkers, aiding in the diagnosis and with a role in prognosis, where, in some settings, they are associated with aggressive behaviour. In this study, we evaluated the performance of TERTmonitor for TERTp genotyping in a series of 185 gliomas in comparison to the traditional method, Sanger sequencing. Against the gold-standard Sanger method, TERTmonitor performed with a 97.8% accuracy. Inaccuracy was mainly due to the over-detection of variants in negative cases (by Sanger) and the presence of variants that can modify the chemistry of the probe detection. The distribution of the mutations was comparable to other series, with the −124 being the most represented (38.92% for Sanger and TERTmonitor) and more prevalent in the higher-grade tumours, gliosarcoma (50.00%) and glioblastoma (52.6%). The non-matched cases are debatable, as we may be dealing with the reduced sensitivity of Sanger in detecting rare alleles, which strengthens the use of the TERTmonitor. With this study, we present a reliable and rapid potential tool for TERTp genotyping in gliomas.Keywords
Funding Information
- Fundação para a Ciência e a Tecnologia (2022.00276.CEECIND, PTDC/MED-ONC/0531/2021, UID/BIM/04293/2019, NORTE-01-0145-FEDER-000051, NORTE-01-0145-FEDER-072678, C644919832-00000035)
- Institute for Research and Innovation in Health Sciences (2022.00276.CEECIND, PTDC/MED-ONC/0531/2021, UID/BIM/04293/2019, NORTE-01-0145-FEDER-000051, NORTE-01-0145-FEDER-072678, C644919832-00000035)
- Norte Portugal Regional Operational Programme (NORTE 2020) (2022.00276.CEECIND, PTDC/MED-ONC/0531/2021, UID/BIM/04293/2019, NORTE-01-0145-FEDER-000051, NORTE-01-0145-FEDER-072678, C644919832-00000035)
- Consórcio PORTO.CCC—Porto.Comprehensive Cancer Center Raquel Seruca (2022.00276.CEECIND, PTDC/MED-ONC/0531/2021, UID/BIM/04293/2019, NORTE-01-0145-FEDER-000051, NORTE-01-0145-FEDER-072678, C644919832-00000035)
- PRR—Plano de Recuperação e Resiliência e pelos Fundos Europeus NextGenerationEU, através do sistema de incentivos «Agendas para a Inovação Empresarial» (2022.00276.CEECIND, PTDC/MED-ONC/0531/2021, UID/BIM/04293/2019, NORTE-01-0145-FEDER-000051, NORTE-01-0145-FEDER-072678, C644919832-00000035)
This publication has 40 references indexed in Scilit:
- Frequency of TERT promoter mutations in human cancersNature Communications, 2013
- High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesionsNature Communications, 2013
- Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q lossActa Neuropathologica, 2013
- Highly prevalent TERT promoter mutations in aggressive thyroid cancersEndocrine-Related Cancer, 2013
- TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewalProceedings of the National Academy of Sciences, 2013
- Highly Recurrent TERT Promoter Mutations in Human MelanomaScience, 2013
- TERT Promoter Mutations in Familial and Sporadic MelanomaScience, 2013
- Comparison of Sanger Sequencing, Pyrosequencing, and Melting Curve Analysis for the Detection of KRAS MutationsThe Journal of Molecular Diagnostics, 2010
- PCR-amplification of GC-rich regions: 'slowdown PCR'Nature Protocols, 2008
- Limitations of stereotactic biopsy in the initial management of gliomasNeuro-Oncology, 2001